PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris
Open Access
- 13 March 2023
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (6) , 770-782
Abstract
In vitro combination of echinocandins and isavuconazole against the emerging species Candida auris is mainly synergistic. However, this combination has not been evaluated in clinical settings. A pharmacokinetic/pharmacodynamic modeling and simulation approach based on in vitro data may be helpful to further study the therapeutic potential of these combinations. Therefore, the aims of this study were to characterize the time course of growth and killing of C. auris in response to the combination of the three approved echinocandins and isavuconazole using a semimechanistic model and to perform model‐based simulations in order to predict the in vivo response to combination therapy. In vitro static time‐kill curve data for isavuconazole and echinocandins combinations against six blood isolates of C. auris were best modeled considering the total killing of the fungal population as dependent on the additive effects of both drugs. Once assessed, the predictive performance of the model using simulations of different dosing and fungal susceptibility scenarios were conducted. Model‐based simulations revealed that none of the combinations at standard or higher dosages would be effective against the studied isolates of C. auris and it was predicted that the combinations of isavuconazole with anidulafungin or caspofungin would be effective for minimum inhibitory concentrations up to 0.03 and 0.06 mg/L respectively, whereas the combination with micafungin would lead to treatment failure. The current approach highlights the importance of bridging the in vitro results to the clinic.Keywords
This publication has 48 references indexed in Scilit:
- Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial DrugsPharmacological Reviews, 2013
- Inhibitory and Fungicidal Effects of Antifungal Drugs against Aspergillus Species in the Presence of SerumAntimicrobial Agents and Chemotherapy, 2013
- Antifungal Activity of Micafungin in SerumAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics and Tissue Distribution of Anidulafungin in RatsAntimicrobial Agents and Chemotherapy, 2008
- Effects of Serum on In Vitro Susceptibility Testing of EchinocandinsAntimicrobial Agents and Chemotherapy, 2007
- Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curvesExpert Opinion on Drug Discovery, 2007
- Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent NeutropeniaAntimicrobial Agents and Chemotherapy, 2007
- Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated CandidiasisAntimicrobial Agents and Chemotherapy, 2006
- Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug ActivityAntimicrobial Agents and Chemotherapy, 2005
- Combination Treatment of Invasive Fungal InfectionsClinical Microbiology Reviews, 2005